This is the authors' abstract. We don't add key points for this paper.
To the Editor: Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (HER2) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.1 Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with HER2 amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.2 On the basis of its mechanism of action, . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Paik et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: